Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
56%(5 trials)

Phase Distribution

Ph phase_3
5
50%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(9)

Detailed Status

Completed9
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 35 (62.5%)

Trials by Status

completed990%
enrolling_by_invitation110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT02137850Phase 3

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

Completed
NCT04682145

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Enrolling By Invitation
NCT04334057

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Completed
NCT03528551Phase 3

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

Completed
NCT01480180Phase 3

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Completed
NCT01731600Phase 3

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Completed
NCT01489111Phase 3

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.

Completed
NCT02994407Phase 1

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

Completed
NCT02920398Phase 1

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Completed
NCT01205724Phase 1

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10